Report Library
All Reports
Q3 2015 Outlook Report
July 09, 2015
In this quarter's report, we cover catalysts from 24 drugs, devices and diagnostics. We have also included a list of Large Impact catalysts
in the drug and device/diagnostic areas through Q3 2015 from our sister product, CatalystTracker. In addition, each drug’s likelihood of
Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are
provided.
Our Q2 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 100% of catalyst outcomes that occurred in Q2 2015.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
For our disclosures, please read the BioMedTracker Research Standards.
Our Q2 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 100% of catalyst outcomes that occurred in Q2 2015.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: |
Alzheimer's Disease (AD)
Atopic Dermatitis (Eczema) Behçet Syndrome Breast Cancer Chemotherapy Induced Nausea and Vomiting (CINV) Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) Chronic Idiopathic Constipation Crohn's Disease Diabetes Mellitus, Type I Dyslipidemia / Hypercholesterolemia Female Sexual Arousal Disorder Glaucoma / Ocular Hypertension (Ophthalmology) Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Hypophosphatasia Lysosomal Acid Lipase Deficiency Major Depressive Disorder (MDD) Mesothelioma Neuroendocrine Tumors (NET) Non-Small Cell Lung Cancer (NSCLC) Schizophrenia |
Additional Resources: